ARTICLE | doi:10.20944/preprints202306.0140.v1
Subject: Medicine And Pharmacology, Clinical Medicine Keywords: familial dysbetalipoproteinemia; hyperlipoproteinemia type III; APOE; apolipoprotein E; apolipoprotein B; autosomal dominant; remnant lipoproteins; hyperlipidemia; population; genetic
Online: 2 June 2023 (08:53:37 CEST)
Familial dysbetalipoproteinemia (FD) is a highly atherogenic genetically-based lipid disorder with the underestimated actual prevalence. In the recent years, several biochemical algorithms have been developed to diagnose FD using available laboratory tests. However, there is not enough data on their use in real-world clinical implementation. We studied the applicability of the most accessible biochemical algorithms to diagnose FD in clinical practice. We also investi-gated the prevalence of FD in one of the European regions of Russia based on a population sample. In this study there was detected a high prevalence of FD: 1 in 151. We demonstrated that the diagnostic algorithms of FD including a diagnostic apoB levels require correction, taking into account the characteristics of the distribution of apoB levels in the population. At the same time a triglycerides cutoff ≥1.5 mmol/L may be a useful tool in identifying subjects with FD. We also analyzed the presence and pathogenicity of APOE variants associated with the autosomal dominant FD in a large research sample.